Adocia’s human glucagon safe, tolerable for type 1 diabetes

People with type 1 diabetes can be safely treated with Adocia’s ready-to-inject aqueous formulation of human glucagon, according to a company press release.

In a recent phase 1 study, participants with type 1 diabetes received continuous intravenous insulin infusion to induce plasma glucose to the range of 56 mg/dL to 60 mg/dL. Researchers assigned participants to subcutaneous single fixed doses of human glucagon as either Adocia’s BioChaperone Glucagon or Novo Nordisk’s lyophilized powder reconstituted immediately prior to injection (GlucaGen HypoKit) to determine the safety and tolerability of each. An acceptable safety and tolerability profile was observed following a single subcutaneous injection of a 1 mg dose of BioChaperone Glucagon. The most common adverse event was nausea with eight events in 25 participants for BioChaperone Glucagon vs. five events in 24 participants with GlucaGen HypoKit.

“We are very pleased to report positive topline results for the clinical trial of BioChaperone Glucagon, the only stable aqueous formulation of human glucagon in development,” Stainislav Glezer, MD, chief medical officer of Adocia, said in the release. “Together with positive stability data, this first set of clinical data supports its further development as a ready-to-inject treatment for severe hypoglycemia. We are currently selecting an easy-to-use state-of-the-art injection device for BioChaperone Glucagon, which aims to provide fast and reliable relief to patients living with diabetes and their caregivers in a situation of hypoglycemia emergency.”